Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

What Was Tested

Researchers studied Survodutide in this randomized controlled trial publication.

Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treating obesity and related diseases.

The SYNCHRONIZE-MASLD phase 3, randomized, double-blind, placebo-controlled trial included 216 adults (131 female and 85 male) with obesity (defined as a body mass index ≥30 kg m-2 or ≥27 kg m-2 with at least one obesity complication) and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD), defined by MASLD with evidence of liver inflammation and/or fibrosis by noninvasive tests (NITs) or biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH).

Who Took Part

The study group was 216 adults.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Survodutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the adults and researchers unaware of who received Survodutide.

Some adults received a placebo instead of Survodutide, giving a reference point.

What Was Measured

The SYNCHRONIZE-MASLD phase 3, randomized, double-blind, placebo-controlled trial included 216 adults (131 female and 85 male) with obesity (defined as a body mass index ≥30 kg m-2 or ≥27 kg m-2 with at least one obesity complication) and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD), defined by MASLD with evidence of liver inflammation and/or fibrosis by noninvasive tests (NITs) or biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH).

PubMed files the paper under topics including Obesity, Fatty Liver, Liver, Magnetic Resonance Imaging and Body Mass Index.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Survodutide in 216 adults.

The publication is from 2026 (Nature medicine), a journal based in United States.

More context: the Survodutide compound page, all human trials.